Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of ONO-4685 in Healthy Male Subjects
NCT04079062Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of ONO-4685 in T-cell lymphoma and autoimmune diseases (5 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Adverse events up to 84 days, Vital sign up to 84 days and 4 more. Started Sep 2019; status: completed.
02
Drugs
ONO-4685
03
Conditions
T-cell lymphomaautoimmune diseases
Beyond the preview
Go deeper on NCT04079062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079062.